Literature DB >> 12385818

Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.

M Alam1, W J Schmidt.   

Abstract

Rotenone (an inhibitor of mitochondrial NADH dehydrogenase, a naturally occurring toxin and a commonly used pesticide) appears to reproduce the neurochemical, neuropathological and behavioural feature of Parkinson's disease (PD) in the rat. In this study, rotenone was administrated on a daily basis systemically by intraperitoneal injection of two different doses: 1.5 mg/kg (low dose) and 2.5 mg/kg (moderate dose), over a period of 2 months. This treatment caused depletion of dopamine in the posterior striatum (CPu) and prefrontal cortex and also reduced tyrosine hydroxylase-immunoreactivity in CPu. Behavioural experiments showed dose-dependent catalepsy in the two treatment groups of rats. Data from this study indicate that in rats rotenone is capable of causing degeneration of dopaminergic neurons and induction of parkinsonian symptoms. It is concluded that the causal mechanisms of neuronal degeneration implicate a complex I deficiency in the aetiology of rotenone-induced and perhaps in some cases of sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385818     DOI: 10.1016/s0166-4328(02)00180-8

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  116 in total

1.  Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.

Authors:  Camila G Moreira; Janaína K Barbiero; Deborah Ariza; Patrícia A Dombrowski; Pamela Sabioni; Mariza Bortolanza; Claudio Da Cunha; Maria A B F Vital; Marcelo M S Lima
Journal:  Neurotox Res       Date:  2011-09-28       Impact factor: 3.911

Review 2.  Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives.

Authors:  Khosro Jamebozorgi; Eskandar Taghizadeh; Daryoush Rostami; Hosein Pormasoumi; George E Barreto; Seyed Mohammad Gheibi Hayat; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-11-05       Impact factor: 5.590

Review 3.  Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.

Authors:  Fernando Calahorro; Manuel Ruiz-Rubio
Journal:  Invert Neurosci       Date:  2011-11-08

Review 4.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

5.  Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease.

Authors:  Zakiya Qualls; Dwayne Brown; Carlana Ramlochansingh; Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-01       Impact factor: 3.911

6.  The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin.

Authors:  William M Johnson; Amy L Wilson-Delfosse; Shu G Chen; John J Mieyal
Journal:  Ther Targets Neurol Dis       Date:  2015

7.  Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells.

Authors:  Akinyinka O Alabi; Abayomi M Ajayi; Benneth Ben-Azu; Osarume Omorobge; Solomon Umukoro
Journal:  Metab Brain Dis       Date:  2019-08-28       Impact factor: 3.584

8.  Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease.

Authors:  Bong-Suk Choi; Hyool Kim; Hyo Jeong Lee; Kumar Sapkota; Se Eun Park; Seung Kim; Sung-Jun Kim
Journal:  Neurochem Res       Date:  2013-11-09       Impact factor: 3.996

9.  Rutin from Dendropanax morbifera Leveille protects human dopaminergic cells against rotenone induced cell injury through inhibiting JNK and p38 MAPK signaling.

Authors:  Se-Eun Park; Kumar Sapkota; Jun-Hui Choi; Myung-Kon Kim; Young Hoi Kim; Ki Man Kim; Kyung Je Kim; Ha-Na Oh; Sung-Jun Kim; Seung Kim
Journal:  Neurochem Res       Date:  2014-02-19       Impact factor: 3.996

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.